Tirzepatide: The Revolution in Hunger Control and its High Effectiveness in Weight Loss
Tirzepatide, marketed in Brazil under the name Mounjaro, It has emerged as one of the most impactful treatments in modern medicine, not only for type 2 diabetes, but primarily for its extraordinary ability to promote weight loss. Its success lies in an innovative mechanism that acts directly on the body's hunger and satiety signals, offering results that surpass those of many previous therapies.
Below is a detailed guide on how tirezpatide works to reduce hunger and its actual effectiveness for weight loss, considering the Brazilian context.
The Dual Mechanism of Action: How Does Tirzepatide Silence Hunger?
The great advantage of tirnezitade is that it is the first and only activator of receptors of two hormones essential intestinal proteins, known as incretins:
GLP-1 (Glucagon-like Peptide-1): Already known for its use in other medications for diabetes and weight loss (such as semaglutide), GLP-1 acts in the brain to increase the feeling of fullness, as well as delaying stomach emptying.
GIP (Glucose-Dependent Insulinotropic Polypeptide): The innovation of tirnezitade lies in also activating GIP receptors, which, together with GLP-1, have been shown to enhance the effects on appetite control and fat metabolism.
This synergistic and dual action translates into powerful and direct effects on reducing hunger:
Activities at the Satiety Center: Tirzepatide acts directly on the hypothalamus, the region of the brain that regulates appetite. It "informs" the brain that the body is satisfied, even if food intake has been lower.
Delayed Gastric Emptying: The medication causes food to remain in the stomach for longer. This slower digestion prolongs the feeling of being "full" after a meal, reducing the urge to eat between main mealtimes.
Reducing "Feeding Noise": Patients undergoing treatment frequently report a drastic decrease in recurring thoughts about food, "emotional hunger," and cravings for high-calorie foods. Control over food choices becomes easier and more natural.
In summary, tirrizepatide does not actively "burn" fat, but rather adjusts the body's appetite thermostat, causing the person to feel satisfied with less food and for longer, leading to a sustainable calorie deficit and significant weight loss.
Proven Efficacy: What Do Clinical Studies Reveal?
The effectiveness of tirnezitalide in weight loss has been extensively validated by a series of global clinical studies. SURMOUNT. The results are considered a watershed moment in the treatment of obesity.
Historical Weight Loss: In the SURMOUNT-1 study, which evaluated the drug in people with obesity but without diabetes, participants who used the highest dose (15 mg) achieved a average body weight loss of 22.5% over 72 weeks. For a person weighing 100 kg, this represents a reduction of more than 22 kg.
Superior Results: Comparative studies have shown that tirrizepatide provides greater weight loss than drugs that activate only the GLP-1 receptor, such as semaglutide.
Comprehensive Health Improvement: In addition to significant weight loss, studies have shown consistent benefits in other health indicators:
Significant reduction in waist circumference.
Improvement in blood pressure levels.
A drop in LDL cholesterol and triglyceride levels.
Improved glycemic control and insulin resistance.
It is crucial to highlight that the best results are achieved when medication is combined with lifestyle changes, such as a balanced diet and regular exercise.
Scenario of Tirzepatida (Mounjaro) in Brazil
Approval from Anvisa: The Brazilian National Health Surveillance Agency (Anvisa) approved Mounjaro in September 2023. The official indication in the package insert, to date, is for... treatment of adults with type 2 diabetes mellitus.
Off-label use for weight loss: Although specific approval for obesity as a chronic disease is still pending at Anvisa (Brazilian Health Regulatory Agency), "off-label" (outside the indications in the package insert) prescription for weight loss is already a reality in Brazilian clinics. This practice is legal and common, based on robust scientific evidence of the drug's efficacy and safety for this purpose.
Availability and Prescription: Mounjaro is already available in the main pharmacy chains across the country. It is sold only with a doctor's prescription.. Self-medication is contraindicated and dangerous.
Administration and Cost: Tirzepatide is administered via a weekly subcutaneous injection using a single-use applicator that is very simple to use. The cost of treatment is still high, and this is a factor to be discussed openly with your doctor.
Conclusion: Tirzepatide represents the cutting edge in the pharmacological treatment of obesity, offering new hope to patients through its potent and dual hunger-reducing mechanism. Its scientifically validated efficacy positions it as a transformative tool, but its use should always be supervised by a qualified healthcare professional to ensure safety and achieve the best results.
